CIBMTR Reporting Implementation Guide
0.1.10 - Trial Use 1
CIBMTR Reporting Implementation Guide
0.1.10 - Trial Use 1
This page is part of the CIBMTR Reporting Implementation Guide (v0.1.10: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions
| Official URL: http://fhir.nmdp.org/ig/cibmtr-reporting/ValueSet/med-prior-exposure-vs | Version: 0.1.10 | |||
| Draft as of 2026-04-23 | Computable Name: RxNormPriorExposureVS | |||
Prior Exposure: Potential Study Eligibility
References
http://www.nlm.nih.gov/research/umls/rxnorm version Not Stated (use latest from terminology server)| Code | Display |
| 10473 | thiotepa |
| 1156487 | thiotepa Injectable Product |
| 1185673 | Mylotarg Injectable Product |
| 1294580 | gemtuzumab ozogamicin |
| 1294581 | gemtuzumab ozogamicin 1 MG/ML |
| 1294582 | gemtuzumab ozogamicin Injectable Product |
| 1294583 | gemtuzumab ozogamicin Injectable Solution |
| 1294584 | gemtuzumab ozogamicin 1 MG/ML Injectable Solution |
| 1366537 | Tepadina |
| 1597258 | blinatumomab |
| 1597260 | blinatumomab Injectable Product |
| 1597262 | blinatumomab 0.035 MG Injection |
| 1597263 | Blincyto |
| 1597266 | Blincyto Injectable Product |
| 1597267 | blinatumomab 0.035 MG Injection [Blincyto] |
| 1651249 | blinatumomab 0.035 MG |
| 1651250 | blinatumomab Injection |
| 1651252 | blinatumomab 0.035 MG [Blincyto] |
| 1651253 | blinatumomab Injection [Blincyto] |
| 1660002 | thiotepa 100 MG |
| 1660003 | thiotepa Injection |
| 1660004 | thiotepa 100 MG Injection |
| 1660008 | thiotepa 15 MG |
| 1660009 | thiotepa 15 MG Injection |
| 1919206 | thiotepa 100 MG [Tepadina] |
| 1919207 | thiotepa Injection [Tepadina] |
| 1919208 | Tepadina Injectable Product |
| 1919209 | thiotepa 100 MG Injection [Tepadina] |
| 1919210 | thiotepa 15 MG [Tepadina] |
| 1919211 | thiotepa 15 MG Injection [Tepadina] |
| 1942950 | inotuzumab ozogamicin |
| 1942951 | inotuzumab ozogamicin 0.9 MG |
| 1942952 | inotuzumab ozogamicin Injectable Product |
| 1942953 | inotuzumab ozogamicin Injection |
| 1942954 | inotuzumab ozogamicin 0.9 MG Injection |
| 1942955 | Besponsa |
| 1942956 | inotuzumab ozogamicin 0.9 MG [Besponsa] |
| 1942957 | inotuzumab ozogamicin Injection [Besponsa] |
| 1942958 | Besponsa Injectable Product |
| 1942959 | inotuzumab ozogamicin 0.9 MG Injection [Besponsa] |
| 1944699 | gemtuzumab ozogamicin 4.5 MG |
| 1944700 | gemtuzumab ozogamicin Injection |
| 1944701 | gemtuzumab ozogamicin 4.5 MG Injection |
| 1944702 | gemtuzumab ozogamicin 4.5 MG [Mylotarg] |
| 1944703 | gemtuzumab ozogamicin Injection [Mylotarg] |
| 1944704 | gemtuzumab ozogamicin 4.5 MG Injection [Mylotarg] |
| 2054068 | mogamulizumab |
| 2054077 | mogamulizumab-kpkc |
| 2054078 | mogamulizumab-kpkc 4 MG/ML |
| 2054079 | mogamulizumab Injectable Product |
| 2054080 | mogamulizumab Injection |
| 2054081 | 5 ML mogamulizumab-kpkc 4 MG/ML Injection |
| 2054082 | Poteligeo |
| 2054083 | mogamulizumab-kpkc 4 MG/ML [Poteligeo] |
| 2054084 | mogamulizumab Injection [Poteligeo] |
| 2054085 | Poteligeo Injectable Product |
| 2054086 | 5 ML mogamulizumab-kpkc 4 MG/ML Injection [Poteligeo] |
| 261585 | Mylotarg |
Expansion from tx.fhir.org based on codesystem RxNorm version 03022026
This value set contains 58 concepts
Explanation of the columns that may appear on this page:
| Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
| System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance) |
| Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |